Western Radiation Oncology, 2500 Grant Road, Mountain View, CA 94040, USA.
Expert Opin Drug Discov. 2011 Feb;6(2):195-203. doi: 10.1517/17460441.2011.546395.
Motexafin gadolinium is a radiation sensitizer that is in the class of drugs known as texaphyrins. Though this drug is currently not FDA approved in the management of brain tumors, several prospective studies have been done showing promise with this agent, which this review highlights.
This paper provides a clinical context by reviewing the background of radiosensitizers, followed by a review of the preclinical discovery of motexafin gadolinium and its clinical testing. We also highlight its most promising applications and comment on the reasons for the observed clinical outcomes.
Motexafin gadolinium is a novel radiosensitizer with clearly documented efficacy, particularly in patients with brain metastases. If this agent had been tested upfront in patients diagnosed with brain metastases from NSCLC who had not been delayed by the administration of systemic chemotherapy, it may have become part of the standard of care in this setting. Continued investigations using this agent are under way and remain promising.
莫替沙芬钆是一种辐射增敏剂，属于卟啉类药物。尽管该药目前尚未获得美国食品和药物管理局（FDA）批准用于脑瘤的治疗，但多项前瞻性研究显示该药物具有一定的应用前景，本文对此进行了综述。
本文通过回顾辐射增敏剂的背景，首先提供了临床背景，然后对莫替沙芬钆的临床前发现及其临床研究进行了综述。本文还突出了它最有前途的应用，并就观察到的临床结果的原因进行了评论。
莫替沙芬钆是一种新型辐射增敏剂，具有明确的疗效，特别是在脑转移患者中。如果该药物在非小细胞肺癌脑转移患者中进行了早期检测，并且没有因全身化疗而延迟，那么它可能已经成为该治疗方案的标准。目前正在进行使用该药物的进一步研究，前景依然乐观。
